The scientific aim of PerMediK is to support the development of a path towards personalized medicine in chronic kidney disease (CKD), based on multidimensional omics data (Big Data).
Ample molecular data, promising therapeutic targets, and markers make it possible to move to the next step of clinical implementation. However, this is stalled by communication gaps, lack of proper multi-disciplinary interactions, and maintenance of isolated rather than coordinated activities.
The PerMediK action provides a multi-disciplinary communication/dissemination platform bringing together a collation of pan-European expertise, representing diverse scientific fields (nephrology, several –omics areas, bioinformatics, biomarker, and drug development), origin (academia, industry, links to policymakers and patient groups), and career levels.
The goal is to allow maximal use of existing resources and coordinate activities on all critical aspects of CKD personalized medicine. The expected impact includes accelerating the introduction of new technologies and therapies for the benefit of CKD patients and promoting European research as a whole.
Delta4’s Computational Biology Lead Dr. Paul Perco represents Austria in the management committee of PerMediK. Initiated by Prof Joachim Jankowski from the University Hospital RWTH Aachen (GER). Several renowned institutions are part of this multi-national initiative such as, for example, the Institut national de la santé et de la recherche médicale (Inserm, FRA), the Biomedical Research Foundation Academy of Athens (BRFAA, GRE), or the University of Glasgow (UK).
The kick-off meeting of this 4-year COST action took place in Brussels in October 2022. The following working groups meeting is planned for March 2023, organized by Prof Constantinos Deltas from the University of Cyprus.